https://biotechmorning.com/news/gsk-survival-bomb-lung-cancer Biotech Morning en 2026-09-13T14:19:17.279Z GSK Just Dropped a Survival Bomb on Lung Cancer's Biggest Players https://biotechmorning.com/news/fda-approves-camizestrant-after-negative-advisory-vote Biotech Morning en 2026-09-13T14:18:30.486Z The Breast Cancer Drug the FDA Said Yes to After Experts Said No https://biotechmorning.com/news/alexander-disease-first-drug-zanvastro-ionis Biotech Morning en 2026-09-13T14:17:41.814Z The Disease Nobody Could Treat Just Got Its First Drug https://biotechmorning.com/news/car-t-autoimmune-safety-crisis Biotech Morning en 2026-09-13T14:16:53.934Z CAR-T's Biggest Bet Outside Cancer Just Hit a Wall https://biotechmorning.com/news/gsk-mrna-flu-vaccine-phase-3-2 Biotech Morning en 2026-09-13T14:16:05.241Z GSK Is Betting mRNA Can Kill Its Own Cash Cow https://biotechmorning.com/news/car-t-after-car-t-failure-pepromene Biotech Morning en 2026-09-13T14:15:20.832Z A CAR-T for Patients Who Already Failed CAR-T https://biotechmorning.com/news/sarepta-black-box-warning-layoffs-gene-therapy-crisis Biotech Morning en 2026-09-13T14:14:40.540Z Sarepta's Worst Week: A Black Box, 500 Pink Slips, and a Gene Therapy in Crisis https://biotechmorning.com/news/first-drug-fixes-narcolepsy-orexin-agonist Biotech Morning en 2026-09-13T14:13:54.055Z The First Drug That Actually Fixes What's Broken in Narcolepsy https://biotechmorning.com/news/tam-peli-sclc-phase-3-death-risk Biotech Morning en 2026-09-13T14:13:09.416Z The Lung Cancer Drug That Cut Death Risk in Half https://biotechmorning.com/news/ivonescimab-beats-keytruda-lung-cancer Biotech Morning en 2026-09-13T14:12:19.210Z The Drug That Just Dethroned the King of Cancer https://biotechmorning.com/news/fda-new-cancer-boss-ai-staffing-plan Biotech Morning en 2026-09-12T14:15:31.806Z The FDA's New Cancer Boss Has a Plan (and It Involves Robots) https://biotechmorning.com/news/solstice-oncology-225m-bet-cold-tumors Biotech Morning en 2026-09-12T14:14:50.075Z A $225M Bet That Cold Tumors Can Learn to Fight Back https://biotechmorning.com/news/astrazeneca-camizestrant-serena-4-failure Biotech Morning en 2026-09-12T14:14:05.500Z AstraZeneca's Cancer Pill Got Approved. Eight Days Later, It Flopped. https://biotechmorning.com/news/sma-muscle-targeted-therapy-apitegromab-approval Biotech Morning en 2026-09-12T14:13:23.074Z The Drug That Treats SMA by Ignoring the Root Cause https://biotechmorning.com/news/exelixis-fda-delay-colorectal-cancer Biotech Morning en 2026-09-12T14:12:35.657Z Exelixis Was Three Months From an Answer. Then the FDA Hit Pause. https://biotechmorning.com/news/fda-commissioner-tried-to-kill-kalvista-drug-approval Biotech Morning en 2026-09-12T14:11:54.689Z The FDA Commissioner Who Tried to Kill a Drug Approval https://biotechmorning.com/news/jj-spravato-patent-victory-2035 Biotech Morning en 2026-09-12T14:11:05.463Z J&J Just Locked Down a $5 Billion Drug Until 2035. Generics Can't Touch It. https://biotechmorning.com/news/personalized-mrna-cancer-vaccine-phase-3-win Biotech Morning en 2026-09-12T14:10:23.900Z The Cancer Vaccine That Just Changed Everything https://biotechmorning.com/news/gene-therapy-worst-week-sarepta-crisis Biotech Morning en 2026-09-12T14:09:36.240Z Gene Therapy's Worst Week Just Got Worse